Proteasome Inhibition as a New Therapeutic Principle in Hematological Malignancies

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|7|10|1341-1347

ISSN： 1389-4501

Source： Current Drug Targets, Vol.7, Iss.10, 2006-10, pp. : 1341-1347

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib: Proteasome Inhibition as a Novel Mechanism of Cancer Therapy-Implications for Hematological Malignancies

By  

Letters in Drug Design & Discovery, Vol. 4, Iss. 2, 2007-03 ,pp. : 82-86

Bentham Science Publishers

Access to resources Recommend Favorite

The Immunoproteasome as a Therapeutic Target for Hematological Malignancies

By  

Current Cancer Drug Targets, Vol. 14, Iss. 6, 2014-07 ,pp. : 537-548

Bentham Science Publishers

Access to resources Recommend Favorite

The JAK-STAT Pathway: A Therapeutic Target in Hematological Malignancies

By  

Current Cancer Drug Targets, Vol. 6, Iss. 8, 2006-01 ,pp. : 671-679

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the proteasome as a therapeutic strategy against haematological malignancies

By Orlowski Robert Z   Zeger Erik L  

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 2, 2006-02 ,pp. : 117-130

Informa Healthcare

Access to resources Recommend Favorite

New nucleoside analogs for patients with hematological malignancies

By Robak Tadeusz  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 3, 2011-03 ,pp. : 343-359

Informa Healthcare

Access to resources Recommend Favorite